Document Detail


Use of erythropoietin in premature neonates: controversies and the future.
MedLine Citation:
PMID:  7756716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review and evaluate current research on the use of recombinant human erythropoietin (rhEPO) for the treatment of anemia of prematurity (AOP). DATA SOURCES: A MEDLINE search (1985-September 1994) was used to identify and retrieve pertinent data about erythropoietin's use in premature neonates. Bibliographies in the relevant literature and International Pharmacy Abstracts were reviewed as well. STUDY SELECTION: The authors extrapolated data from trials and other literature in which the entire paper or abstract was published. Because of the paucity of data on the use of rhEPO in neonates, all available literature was reviewed and cited, regardless of study methodology. DATA SYNTHESIS: Most data support that rhEPO is efficacious in treating AOP. Until recently, the published investigations have included only small numbers of patients. Larger, multicenter, placebo-controlled trials suggest that infants weighing less than 1500 g benefit from rhEPO therapy. Questions remain concerning the rhEPO dose and nutrient requirements for optimal efficacy. CONCLUSIONS: Published clinical trials that have examined the efficacy of rhEPO in the treatment of AOP vary considerably with regard to methodology, rhEPO dose, nutrient doses, and outcome measurement. At present, many questions remain to be answered including ascertaining rhEPO's long-term benefit versus cost/risk as well as its potential contribution to improving the care of the premature neonate.
Authors:
T L Wandstrat; B Kaplan
Related Documents :
15265196 - Isoniazid and hypoglycaemia in a premature infant.
3797326 - Chorioamnionitis: perinatal morbidity and mortality.
19928736 - Importance of the 'third criterion' for retinopathy of prematurity screening in develop...
15616826 - Connatal tuberculosis in a very premature infant.
16303696 - Haematological parameters of hiv-1-uninfected infants born to hiv-1-infected mothers.
3951916 - Electrocardiogram of the premature infant at 1 year of age.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  29     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-06-28     Completed Date:  1995-06-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  166-73     Citation Subset:  IM    
Affiliation:
School of Pharmacy, Robert C. Byrd Health Sciences Center of West Virginia University, Charleston 25304, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / drug therapy*
Clinical Trials as Topic
Economics, Pharmaceutical
Erythropoietin / pharmacology,  therapeutic use*
Female
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / drug therapy*
Male
Randomized Controlled Trials as Topic
Recombinant Proteins / pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stereochemistry in pharmacotherapy: when mirror images are not identical.
Next Document:  Recent advances: parenteral nutrition support.